by Truveta Research | Jan 23, 2026 | Research
Respiratory virus–associated hospitalizations increased substantially (+125.3%) in December 2025 and accounted for nearly 7% of all hospitalizations by the last week of the month. This increase was driven primarily by a rise in influenza-associated hospitalizations...
by Truveta Research | Jan 21, 2026 | Research
From 2018 to 2025, robotic-assisted surgery increased across hysterectomy, cholecystectomy, and inguinal hernia repair, with robotic use in cholecystectomy increasing more than six-fold over the study period. Across all procedures, patients with higher comorbidity...
by Truveta Research | Jan 20, 2026 | Research
As of December 2025, GLP-1 RA prescriptions account for more than 7% of all prescriptions. Tirzepatide continues to be the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and Zepbound, respectively) and showed the largest...
by Truveta staff | Jan 15, 2026 | Research
Type 1 diabetes (T1D) affects far fewer people than type 2, but the stakes for each person are higher. It’s a lifelong, minute-by-minute autoimmune condition. People with T1D depend on insulin to survive, and small improvements in glucose control can translate into...
by Truveta staff | Jan 7, 2026 | Research
For people who experience a first non-cardioembolic ischemic stroke (NCIS) or transient ischemic attack (TIA), the danger doesn’t end at hospital discharge. New research presented at the 2025 World Stroke Congress shows that the risk of recurrent events and...
by Truveta Research | Jan 2, 2026 | Research
Authors: Nina B. Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Karen G. Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...
